Neuren Pharmaceuticals Ltd
ASX:NEU

Watchlist Manager
Neuren Pharmaceuticals Ltd Logo
Neuren Pharmaceuticals Ltd
ASX:NEU
Watchlist
Price: 19.87 AUD 0.61% Market Closed
Market Cap: 2.5B AUD

Neuren Pharmaceuticals Ltd
Free Cash Flow

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Neuren Pharmaceuticals Ltd
Free Cash Flow Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Free Cash Flow CAGR 3Y CAGR 5Y CAGR 10Y
Neuren Pharmaceuticals Ltd
ASX:NEU
Free Cash Flow
AU$137.6m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Recce Pharmaceuticals Ltd
ASX:RCE
Free Cash Flow
-AU$318.3k
CAGR 3-Years
67%
CAGR 5-Years
39%
CAGR 10-Years
N/A
Mayne Pharma Group Ltd
ASX:MYX
Free Cash Flow
-AU$11.5m
CAGR 3-Years
15%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Botanix Pharmaceuticals Ltd
ASX:BOT
Free Cash Flow
-AU$79.6m
CAGR 3-Years
-78%
CAGR 5-Years
-35%
CAGR 10-Years
-52%
C
Clarity Pharmaceuticals Ltd
ASX:CU6
Free Cash Flow
-AU$55m
CAGR 3-Years
-60%
CAGR 5-Years
-52%
CAGR 10-Years
N/A
Nyrada Inc
ASX:NYR
Free Cash Flow
-AU$5.1m
CAGR 3-Years
-20%
CAGR 5-Years
-3%
CAGR 10-Years
N/A
No Stocks Found

Neuren Pharmaceuticals Ltd
Glance View

Market Cap
2.5B AUD
Industry
Pharmaceuticals

Founded in 1993, Neuren Pharmaceuticals Ltd has carved a niche for itself within the biotech industry, focusing primarily on neurological and neurodevelopmental disorders. The company operates at the intriguing intersection of innovation and medicine, where the stakes are high, but so are the potential rewards. Neuren has its headquarters in Australia and has oriented its research towards developing therapies that could change the lives of those affected by conditions like Rett syndrome and Fragile X syndrome. By adopting a strategic approach that combines cutting-edge science with a relentless focus on unmet needs, Neuren positions itself uniquely through its proprietary compounds such as trofinetide and NNZ-2591, which are at the core of its research endeavors. The company's business model hinges on a dual approach: developing its own drugs while simultaneously fostering partnerships with larger pharmaceutical companies to bring these therapies to market. This model allows Neuren to share the substantial costs and risks inherent in drug development while benefiting from the expanse of its partners' distribution networks and market insights. Revenue generation kicks in primarily through milestone payments, royalties, and licensing agreements as these partners help navigate the rigorous phases of clinical trials and regulatory approvals. Financial stability is thus intricately tied to clinical successes and strategic alliances, allowing Neuren to balance the speculative nature of biotech investments with the promise of transformative medical breakthroughs.

NEU Intrinsic Value
HIDDEN
Show

See Also

What is Neuren Pharmaceuticals Ltd's Free Cash Flow?
Free Cash Flow
137.6m AUD

Based on the financial report for Jun 30, 2025, Neuren Pharmaceuticals Ltd's Free Cash Flow amounts to 137.6m AUD.

What is Neuren Pharmaceuticals Ltd's Free Cash Flow growth rate?
Free Cash Flow CAGR 1Y
15%

Over the last year, the Free Cash Flow growth was 15%.

Back to Top